Cooperative research and development agreement

Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Retrieved on: 
Lunedì, Novembre 28, 2022
Legal, Professional Services, Transfer, Tech, United States national laboratories, Cooperative research and development agreement, Palm Springs (2020 film), Silicon, Yale University, Oak Ridge National Laboratory, Life, Private law, Technology transfer, NYSE, Word, Wilson Sonsini Goodrich & Rosati, Research, Cooperative, PDF, Management, Northwestern University

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief licensing advisor (East) in the New York office.

Key Points: 
  • Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief licensing advisor (East) in the New York office.
  • Soderstrom is well known throughout the East Coasts venture capital and academic communities as an expert in technology transfer.
  • Jon was crucial in Yales development of research projects that brought cutting-edge technology and ideas into everyday life, said Ian Edvalson, Wilson Sonsini partner and co-leader of the firms technology transactions practice.
  • His standing within the entrepreneurial community on the East Coast will help Wilson Sonsini develop important relationships with clients.

BAKKEN ENERGY ANNOUNCES PARTNERSHIP WITH THE GRAND FORKS AIR FORCE BASE

Retrieved on: 
Mercoledì, Novembre 16, 2022
Hydrogen, Environment, Hub, Schneider, Organization, GFAFB, Partnership, CRADA, United States Department of the Air Force, Grand Forks, North Dakota, Air force, Fork, Grand Forks Air Force Base, Research, Cooperative research and development agreement, Development, Cummins, Mandan, Hidatsa, and Arikara Nation, Oil

Grand Forks, North Dakota, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bakken Energy, an innovative developer of affordable clean hydrogen at scale has entered into a Cooperative Research and Development Agreement (CRADA) with the Grand Forks Air Force Base (GFAFB) to explore options for future applications of clean hydrogen.

Key Points: 
  • Grand Forks, North Dakota, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bakken Energy, an innovative developer of affordable clean hydrogen at scale has entered into a Cooperative Research and Development Agreement (CRADA) with the Grand Forks Air Force Base (GFAFB) to explore options for future applications of clean hydrogen.
  • Energy is a big part of mission readiness and alternative energy sources provide flexibility for operations.
  • The Department of the Air Force is always looking for ways to implement alternative energy solutions to benefit the environment and to keep us mission ready.
  • We look forward to exploring practical uses of hydrogen with Bakken Energy."

BAKKEN ENERGY ANNOUNCES PARTNERSHIP WITH THE GRAND FORKS AIR FORCE BASE

Retrieved on: 
Martedì, Novembre 15, 2022
Hydrogen, Environment, Hub, Schneider, Organization, GFAFB, Partnership, CRADA, United States Department of the Air Force, Grand Forks, North Dakota, Air force, Fork, Grand Forks Air Force Base, Research, Cooperative research and development agreement, Development, Cummins, Mandan, Hidatsa, and Arikara Nation, Oil

Grand Forks, North Dakota, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bakken Energy, an innovative developer of affordable clean hydrogen at scale has entered into a Cooperative Research and Development Agreement (CRADA) with the Grand Forks Air Force Base (GFAFB) to explore options for future applications of clean hydrogen.

Key Points: 
  • Grand Forks, North Dakota, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bakken Energy, an innovative developer of affordable clean hydrogen at scale has entered into a Cooperative Research and Development Agreement (CRADA) with the Grand Forks Air Force Base (GFAFB) to explore options for future applications of clean hydrogen.
  • Energy is a big part of mission readiness and alternative energy sources provide flexibility for operations.
  • The Department of the Air Force is always looking for ways to implement alternative energy solutions to benefit the environment and to keep us mission ready.
  • We look forward to exploring practical uses of hydrogen with Bakken Energy."

TMD LAB Collaborates With US NIST to Reveal the Secrets of Shape-memory Polymer Materials

Retrieved on: 
Lunedì, Novembre 14, 2022
Health, Medical Devices, Surgery, Health Technology, Research, Science, Biotechnology, Shape-memory polymer, Cooperative research and development agreement, LAB, Silicon, U.S. Department of Commerce Office of Security, NIST, National Institute of Standards and Technology, DNA, Commerce, SMP, Research, Thermoregulation, TMD, Development, Biofilm, U.S. Department of Defense Strategy for Operating in Cyberspace, Medical device, CRADA

TMD LAB received a Cooperative Research and Development Agreement (CRADA) proposal from the NIST and signed the agreement on October 11 2022.

Key Points: 
  • TMD LAB received a Cooperative Research and Development Agreement (CRADA) proposal from the NIST and signed the agreement on October 11 2022.
  • TMD LAB and the biomaterials group of NIST signed a confidential disclosure agreement for joint research in April last year.
  • In addition, basic research on the structural properties of SMP of TMD LAB has been conducted.
  • TMD LAB Co., Ltd., established in 2018, is a company that is developing implantable medical devices using Shape Memory Polymer (SMP), high-tech new materials.

Atmospheric Water Generator Global Market to Reach $9.7 Billion by 2031 at a CAGR of 14.8%

Retrieved on: 
Mercoledì, Novembre 16, 2022
Drinking water, CRADA, Growth, Cooperative research and development agreement, Technology, Water supply, Population, Benchmarking, Porter's five forces analysis, Water, Income, CAGR, Chemical engineering, Indian Institute of Chemical Technology, Institute, Investment, IICT, AWG, Humidity, EPA, Temperature, Capacity, Atmosphere, Germany, Development, Renewable energy, Retail, Watergen

The global atmospheric water generator market size was valued at $2,450.9 million in 2021, and is projected to reach $9,703.5 million by 2031, registering a CAGR of 14.8% from 2022 to 2031.

Key Points: 
  • The global atmospheric water generator market size was valued at $2,450.9 million in 2021, and is projected to reach $9,703.5 million by 2031, registering a CAGR of 14.8% from 2022 to 2031.
  • One of the primary factors driving the growth of the atmospheric water generator market is the global expansion of various policies for improving a country's public water infrastructure and drinking water systems.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atmospheric water generator market analysis from 2021 to 2031 to identify the prevailing atmospheric water generator market opportunities.
  • The report includes the analysis of the regional as well as global atmospheric water generator market trends, key players, market segments, application areas, and market growth strategies.

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Retrieved on: 
Mercoledì, Novembre 9, 2022
IND, Communication, Research, CNMV, Development, Sale, Person, NEC Laboratories America, Survival, Fox Chase Cancer Center, CRADA, Associate, Squamous cell carcinoma, Phase II, NETS, Forward-looking statement, Prevalence, Azacitidine, B cell, ISIN, FLT3, Prospectus, FCCC, Mercado, Cancer, Gastrointestinal tract, AML, Patient, MD, NCI, NET, Investigational New Drug, Cooperative research and development agreement, Hematological Cancer Research Investment and Education Act, Medulloblastoma, EHA, Acute myeloid leukemia, NEC, Mission statement, Public expenditure, Growth, FDA, GLOBE, Carcinoma, ORY, ESMO, Wilms' tumor, Spanish, Safety, LSD1, Genomics, ALICE, Prognosis, Pharmaceutical industry, SCLC, EU

Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.

Key Points: 
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Response rates for NECs and SCLC in second line are generally less than 5% and 20%, respectively, and survival is measured in months.
  • There are very few treatment options for these patients and even fewer trials, which makes this effort even more important.
  • In total iadademstat has been dosed so far to more than 100 cancer patients in four clinical trials.

Atmospheric Water Generator Global Market Report 2022: Expansion of Government Water Infrastructure Policies Boosting Growth - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 10, 2022
Energy, Other Energy, Other Manufacturing, Manufacturing, IICT, Cooperative research and development agreement, Investment, Temperature, AWG, Water supply, EPA, Technology, Development, Population, Porter's five forces analysis, Indian Institute of Chemical Technology, Institute, Atmosphere, Capacity, Water, Humidity, Drinking water, Germany, Benchmarking, CRADA, Growth, Chemical engineering, CAGR, Income, Renewable energy, Retail, Watergen

One of the primary factors driving the growth of the atmospheric water generator market is the global expansion of various policies for improving a country's public water infrastructure and drinking water systems.

Key Points: 
  • One of the primary factors driving the growth of the atmospheric water generator market is the global expansion of various policies for improving a country's public water infrastructure and drinking water systems.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the atmospheric water generator market analysis from 2021 to 2031 to identify the prevailing atmospheric water generator market opportunities.
  • An in-depth analysis of the atmospheric water generator market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global atmospheric water generator market trends, key players, market segments, application areas, and market growth strategies.

ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

Retrieved on: 
Lunedì, Novembre 7, 2022
ORY, Communication, Prospectus, Mercado, Azacitidine, Sale, Society, Spanish, Wilms' tumor, SCLC, GLOBE, ESMO, Squamous cell carcinoma, Safety, Hematological Cancer Research Investment and Education Act, IND, Ernest, Vall, FLT3, ASH, NCI, Medulloblastoma, NET, Acute myeloid leukemia, CNMV, Patient, Transplant, EHA, ISIN, ALICE, Mission statement, Cooperative research and development agreement, Clinical trial, Forward-looking statement, BCL2, LSD1, Development, CRADA, Exposition, Genomics, Public expenditure, AML, Person, MD, Cancer, Cellular, Pharmaceutical industry, EU

Dr. Carlos Buesa, Oryzons CEO, said: "These results confirm previous data in supporting a strong synergy between iadademstat and azacitidine in combination.

Key Points: 
  • Dr. Carlos Buesa, Oryzons CEO, said: "These results confirm previous data in supporting a strong synergy between iadademstat and azacitidine in combination.
  • It is highly encouraging that we continue to see high levels of response and extended remissions, alongside good tolerability.
  • A copy of the presentation will be available on Oryzons website at www.oryzon.com following presentation at the meeting.
  • Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European leader in epigenetics.

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Retrieved on: 
Lunedì, Novembre 7, 2022
Drug, MRC Laboratory of Molecular Biology, Laboratory, Neoplasm, NCI, National, Physician, Cooperative research and development agreement, Molecular biology, Cancer, Non-small-cell lung carcinoma, Engineering, Development, CRADA, HIO, Patient, Triple-negative breast cancer, Program, Pharmaceutical industry, Vaccine, Thorax

PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
  • Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate, NAV-001, under the supervision of Dr. Raffit Hassan, Chief of Thoracic and GI Malignancies Branch at the NCI.
  • "NAV-001 has proven to be very effective with single, sub-mg/kg dosing against various patient-derived tumor types in mouse models, causing significant regression of the cancer lesions."
  • Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited therapeutic response of immune-mediated anti-cancer therapies.

ORYZON to Give Updates on Corporate Progress in November

Retrieved on: 
Venerdì, Novembre 4, 2022
EVOLUTION, Pipeline, Medulloblastoma, ISIN, ESCAPE, CNS, Clinical trial, Government budget balance, Schizophrenia, Degenerative disease, Hematological Cancer Research Investment and Education Act, Prospectus, Borderline personality disorder, Moderate, GLOBE, Mouse, IND, FLT3, NCI, NET, EHA, COVID-19, Mission statement, Forward-looking statement, CRADA, Patient, Cancer, ORY, Kabuki syndrome, Azacitidine, MS, Sale, Spanish, Multiple sclerosis, ESMO, Cooperative research and development agreement, LSD1, Aggression, Genomics, Market, Mercado, Time, Wilms' tumor, SCLC, Squamous cell carcinoma, Ageing, Safety, Conference, Neuroinflammation, CNMV, ALICE, AD, Development, Syndrome, Public expenditure, AML, Person, Communication, Amnesia, Pharmaceutical industry, EU

Oryzon will participate at the Inv€$tival Showcase LSX Leaders 2022 conference, which will be held on November 14 in London (United Kingdom). The company will take part in a panel entitled “CNS and the Market -- What is New in the Pipeline and in Deal Activity?”on November 14 at 15:00 local time. Click on link for more info about the Inv€$tival Showcase LSX Leaders conference

Key Points: 
  • Oryzons medical team will participate at the Kabuki Syndrome Foundation Annual Conference, which will be held virtually on November 4.
  • In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases.
  • Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon.
  • This press release is not an offer of securities for sale in the United States or any other jurisdiction.